Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Constructing an efficient trans-acting genomic HDV ribozyme

J Kawakami1, K Yuda, Y A Suh

  • 1Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

FEBS Letters
|September 30, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Centrilobular nodules are predictive chest computed tomography (CT) findings related to adult T-cell leukemia/lymphoma development in human T-lymphotropic virus type I carriers.

Clinical radiology·2024
Same author

Mutation induced by deoxyxanthosine in codon 12 of a synthetic c-Ha-ras gene.

Nucleosides & nucleotides·2018
Same author

Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis.

Bone marrow transplantation·2012
Same author

Correlations of HHV-6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients.

Bone marrow transplantation·2009
Same author

Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation.

Bone marrow transplantation·2007
Same author

Real-time PCR assays based on distinct genomic regions for cytomegalovirus reactivation following hematopoietic stem cell transplantation.

Bone marrow transplantation·2004
Same journal

Regulation of CFTR stability at the plasma membrane-Mechanisms and therapeutic opportunities in cystic fibrosis.

FEBS letters·2026
Same journal

Identification of a Shiga toxin A-derived peptide internalized into Gb3 receptor-bearing cells via interaction with the Shiga toxin B subunit.

FEBS letters·2026
Same journal

The dual role of lectins in cancer-immunotherapy tools and therapeutic targets.

FEBS letters·2026
Same journal

Decoding the dynamic extracellular matrix in cancer-3D models and bioscaffolds rewire the rules of tumor progression.

FEBS letters·2026
Same journal

Extending the classical sequence-structure-function paradigm through protein dynamics and context-dependent behavior.

FEBS letters·2026
Same journal

α-Synuclein aggregation landscape from phase separation to neurotoxic intermediates.

FEBS letters·2026
See all related articles

Researchers engineered a highly active genomic Hepatitis Delta Virus (HDV) ribozyme for trans-cleavage of target RNAs. The optimized HDV88-Trans-4 variant shows significantly enhanced in vitro activity under physiological conditions.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • RNA Therapeutics

Background:

  • Genomic HDV ribozymes are catalytic RNA molecules.
  • Trans-acting ribozymes cleave target RNAs in a separate molecule.
  • Engineering ribozymes for enhanced function is an active research area.

Purpose of the Study:

  • To engineer a more efficient trans-acting genomic HDV ribozyme.
  • To improve the in vitro cleavage activity of existing HDV ribozymes.
  • To characterize ribozyme variants under physiological conditions.

Main Methods:

  • Engineering of multiple trans-acting HDV ribozyme variants.
  • In vitro cleavage assays using a 13-nucleotide substrate (R13).
  • Analysis of cleavage rate constants (kclv) for different variants.

Related Experiment Videos

  • Optimization of stem II length in the pseudoknot structure.

    • Main Results:

    • HDV88-Trans showed initial in vitro cleavage activity.
    • A variant, HDV88-Trans-4, exhibited a significant increase in cleavage efficiency (kclv = 1.7 min-1).
    • This represents the most active trans-acting genomic HDV ribozyme constructed to date.
    • HDV88-Trans-4 demonstrated activity under physiological conditions (pH 7.1, 37°C, 1 mM MgCl2).

    Conclusions:

    • HDV88-Trans-4 is a highly active trans-acting genomic HDV ribozyme.
    • Structural modifications, specifically to stem II, enhance ribozyme activity.
    • This engineered ribozyme holds potential for RNA-targeting applications under physiological conditions.